Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

Impact · against what's priced in

BDTX provides a high-convexity opportunity as its current valuation ignores the clinical efficacy of Silevertinib and trades below its net cash position. The strong Phase 2 ORR and sufficient liquidity significantly shift the risk/reward profile toward the upside.

BDTX+0.80

No priced-in read yet

In context

Silevertinib's 60% ORR and 86% CNS ORR in NSCLC, combined with a $118M cash runway, provide strong clinical and fundamental catalysts for a stock currently trading below its cash value.

Read from the article alone

• pharmaceuticals
• biotech
• BDTX
• cancer treatment
• cash value
• clinical trials
• nsclc
• oncology
• precision medicine

Search tags